Home HIV FAQ My Amedeo About Flying Publisher   

Amedeo Prize 2008
The 21 Finalists


  HIV Infection

  Free Subscription


Articles published in Vaccine

Retrieve available abstracts of 71 articles:
HTML format



Single Articles


    April 2008
  1. BRAVE A , Hallengard D, Schroder U, Blomberg P, et al
    Intranasal immunization of young mice with a multigene HIV-1 vaccine in combination with the N3 adjuvant induces mucosal and systemic immune responses.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available


  2. GRAY K , Legg K, Sharp A, Mackie N, et al
    Participation in two phase II prophylactic HIV vaccine trials in the UK.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available


  3. VALOR L , Navarro J, Carbone J, Rodriguez-Sainz C, et al
    Immunization with an HIV-1 immunogen induces CD4(+) and CD8(+) HIV-1-specific polyfunctional responses in patients with chronic HIV-1 infection receiving antiretroviral therapy.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available


    March 2008
  4. JAOKO W , Nakwagala FN, Anzala O, Manyonyi GO, et al
    Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available


  5. NEWMAN PA , Duan N, Kakinami L, Roberts K, et al
    What can HIV vaccine trials teach us about future HIV vaccine dissemination?
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available


  6. LECOQ A , Moine G, Bellanger L, Drevet P, et al
    Increasing the humoral immunogenic properties of the HIV-1 Tat protein using a ligand-stabilizing strategy.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available


  7. HIRAO LA , Wu L, Khan AS, Hokey DA, et al
    Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available


    February 2008
  8. YANG OO
    Retracing our STEP towards a successful CTL-based HIV-1 vaccine.
    Vaccine. 2008;.
    PubMed     Related articles   


  9. HUANG Y , Chen A, Li X, Chen Z, et al
    Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available


  10. RASKA M , Moldoveanu Z, Novak J, Hel Z, et al
    Delivery of DNA HIV-1 vaccine to the liver induces high and long-lasting humoral immune responses.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available


  11. SINGH P , Kaur G, Sharma G, Mehra NK, et al
    Immunogenetic basis of HIV-1 infection, transmission and disease progression.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available


  12. HUTCHESON HB , Lautenberger JA, Nelson GW, Pontius JU, et al
    Detecting AIDS restriction genes: From candidate genes to genome-wide association discovery.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available


    January 2008
  13. MIYAZAWA M , Tsuji-Kawahara S, Kanari Y
    Host genetic factors that control immune responses to retrovirus infections.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available


  14. CAPUTO A , Brocca-Cofano E, Castaldello A, Voltan R, et al
    Characterization of immune responses elicited in mice by intranasal co-immunization with HIV-1 Tat, gp140 DeltaV2Env and/or SIV Gag proteins and the nontoxicogenic heat-labile Escherichia coli enterotoxin.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available


  15. VANDEPAPELIERE P , Horsmans Y, Moris P, Van Mechelen M, et al
    Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available


  16. VANGELISTA L , Secchi M, Lusso P
    Rational design of novel HIV-1 entry inhibitors by RANTES engineering.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available


  17. WANG S , Kennedy JS, West K, Montefiori DC, et al
    Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available   Free Full Text


  18. JACOBS A , Garg H, Viard M, Raviv Y, et al
    HIV-1 envelope glycoprotein-mediated fusion and pathogenesis: Implications for therapy and vaccine development.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available


  19. BECK Z , Prohaszka Z, Fust G
    Traitors of the immune system-Enhancing antibodies in HIV infection: Their possible implication in HIV vaccine development.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available


  20. FERNANDES SJ , Slhessarenko N, Souto FJ
    Effects of vertical HIV infection on the persistence of anti-HBs after a schedule of three doses of recombinant hepatitis B vaccine.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available


  21. NEWMAN PA , Daley A, Halpenny R, Loutfy M, et al
    Community heroes or "high-risk" pariahs? Reasons for declining to enroll in an HIV vaccine trial.
    Vaccine. 2008;.
    PubMed     Related articles    Abstract available


    December 2007
  22. YIN L , Zhang Y, Qian HZ, Rui B, et al
    Willingness of Chinese injection drug users to participate in HIV vaccine trials.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available


  23. STOIBER H , Banki Z, Wilflingseder D, Dierich MP, et al
    Complement-HIV interactions during all steps of viral pathogenesis.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available


  24. RIVERA DS , McMurry JA, Buus S, Martin W, et al
    Identification of immunogenic HLA-B7 "Achilles' heel" epitopes within highly conserved regions of HIV.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available


  25. ALVING CR , Rao M
    Lipid A and liposomes containing lipid A as antigens and adjuvants.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available


  26. KOTWAL GJ
    Genetic diversity-independent neutralization of pandemic viruses (e.g. HIV), potentially pandemic (e.g. H5N1 strain of influenza) and carcinogenic (e.g. HBV and HCV) viruses and possible agents of bioterrorism (variola) by enveloped virus neutralizing co
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available


  27. SRIVASTAVA I , Goodsell A, Zhou F, Sun Y, et al
    Dynamics of acute and memory mucosal and systemic immune responses against HIV-1 envelope following immunizations through single or combinations of mucosal and systemic routes.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available


  28. PIACENTINI L , Fenizia C, Naddeo V, Clerici M, et al
    Not just sheer luck! Immune correlates of protection against HIV-1 infection.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available


  29. VELJKOVIC V , Veljkovic N, Glisic S, Ho MW, et al
    AIDS vaccine: Efficacy, safety and ethics.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available


  30. CAGIGI A , Nilsson A, De Milito A, Chiodi F, et al
    B cell immunopathology during HIV-1 infection: Lessons to learn for HIV-1 vaccine design.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available


  31. LEHNER T , Wang Y, Pido-Lopez J, Whittall T, et al
    The emerging role of innate immunity in protection against HIV-1 infection.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available


  32. BAYER W , Schimmer S, Hoffmann D, Dittmer U, et al
    Evaluation of the Friend Virus model for the development of improved adenovirus-vectored anti-retroviral vaccination strategies.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available


  33. GAVIOLI R , Cellini S, Castaldello A, Voltan R, et al
    The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: Implications for the design of new vaccination strategies against AIDS.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available


  34. MARTINON F , Brochard P, Ripaux M, Delache B, et al
    Improved protection against simian immunodeficiency virus mucosal challenge in macaques primed with a DNA vaccine and boosted with the recombinant modified vaccinia virus Ankara and recombinant Semliki Forest virus.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available


  35. WYATT LS , Earl PL, Vogt J, Eller LA, et al
    Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available   Free Full Text


    November 2007
  36. LU L , Zhu Y, Diao J, Wang Z, et al
    V3 CTL epitope density in a single recombinant molecule antigen differentially affects the number and activity of primary and memory CD8(+) T cells.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available


  37. PIALOUX G , Hocini H, Perusat S, Silberman B, et al
    Phase I study of a candidate vaccine based on recombinant HIV-1 gp160 (MN/LAI) administered by the mucosal route to HIV-seronegative volunteers: The ANRS VAC14 study.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available


  38. GORSE GJ , Baden LR, Wecker M, Newman MJ, et al
    Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available


  39. HIRAO LA , Wu L, Khan AS, Satishchandran A, et al
    Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available


  40. MERCIER GT , Nehete PN, Passeri MF, Nehete BN, et al
    Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules.
    Vaccine. 2007;25:8689-8703.
    PubMed     Related articles    Abstract available   Free Full Text


    October 2007
  41. SAINI M , Hadas E, Volsky DJ, Potash MJ, et al
    Vaccine-induced protection from infection of mice by chimeric human immunodeficiency virus type 1, EcoHIV/NL4-3.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available


  42. CAMPBELL GR , Senkaali D, Watkins J, Esquieu D, et al
    Tat mutations in an African cohort that do not prevent transactivation but change its immunogenic properties.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available


  43. GRECO R , Michel M, Guetard D, Cervantes-Gonzalez M, et al
    Production of recombinant HIV-1/HBV virus-like particles in Nicotiana tabacum and Arabidopsis thaliana plants for a bivalent plant-based vaccine.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available


  44. PUTHANAKIT T , Aurpibul L, Yoksan S, Sirisanthana T, et al
    Japanese encephalitis vaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available


  45. CHEN JM , Islam ST, Ren H, Liu J, et al
    Differential productions of lipid virulence factors among BCG vaccine strains and implications on BCG safety.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available


    September 2007
  46. ZHOU Q , Hidajat R, Peng B, Venzon D, et al
    Comparative evaluation of oral and intranasal priming with replication-competent adenovirus 5 host range mutant (Ad5hr)-simian immunodeficiency virus (SIV) recombinant vaccines on immunogenicity and protective efficacy against SIV(mac251).
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available


  47. HAMMONDS J , Chen X, Zhang X, Lee F, et al
    Advances in methods for the production, purification, and characterization of HIV-1 Gag-Env pseudovirion vaccines.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available


  48. HUANG X , Liu L, Ren L, Qiu C, et al
    Mucosal priming with replicative Tiantan vaccinia and systemic boosting with DNA vaccine raised strong mucosal and systemic HIV-specific immune responses.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available


  49. GUILLON C , Mayol K, Terrat C, Compagnon C, et al
    Formulation of HIV-1 Tat and p24 antigens by PLA nanoparticles or MF59 impacts the breadth, but not the magnitude, of serum and faecal antibody responses in rabbits.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available


  50. ELLER MA , Eller LA, Opollo MS, Ouma BJ, et al
    Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA vaccine candidate in healthy Ugandans.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available


  51. JOHNSON LF , Bekker LG, Dorrington RE
    HIV/AIDS vaccination in adolescents would be efficient and practical when vaccine supplies are limited.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available


  52. DONG XN , Chen Y, Chen YH
    Surface simulation synthesis: a new strategy to spy alpha-helix structure.
    Vaccine. 2007;25:6569-71.
    PubMed     Related articles    Abstract available


    August 2007
  53. DUKE CM , Maguire CA, Keefer MC, Federoff HJ, et al
    HSV-1 amplicon vectors elicit polyfunctional T cell responses to HIV-1 Env, and strongly boost responses to an adenovirus prime.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available


  54. AIDOO M , Otten RA, Rodriguez V, Sariol CA, et al
    Absence of SHIV infection in gut and lymph node tissues in rhesus monkeys after repeated rectal challenges following HIV-1 DNA/MVA immunizations.
    Vaccine. 2007;25:6474-81.
    PubMed     Related articles    Abstract available


  55. JIANG S , Rasmussen RA, Nolan KM, Frankel FR, et al
    Live attenuated Listeria monocytogenes expressing HIV Gag: Immunogenicity in rhesus monkeys.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available


  56. KITCHEN LW , Vaughn DW
    Role of U.S. military research programs in the development of U.S.-licensed vaccines for naturally occurring infectious diseases.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available


  57. BEYRER C , Baral S, Shaboltas A, Dukhovlinova E, et al
    The feasibility of HIV vaccine efficacy trials among Russian injection drug users.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available


    July 2007
  58. BRAVE A , Hinkula J, Cafaro A, Eriksson LE, et al
    Candidate HIV-1 gp140DeltaV2, Gag and Tat vaccines protect against experimental HIV-1/MuLV challenge.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available


  59. PARKER SD , Rottinghaus ST, Zajac AJ, Yue L, et al
    HIV-1(89.6) Gag expressed from a replication competent HSV-1 vector elicits persistent cellular immune responses in mice.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available   Free Full Text


  60. HESSELING AC , Cotton MF, Marais BJ, Gie RP, et al
    BCG and HIV reconsidered: Moving the research agenda forward.
    Vaccine. 2007;.
    PubMed     Related articles   


    June 2007
  61. LOUTAN L , Bovier P, Herzog C
    Immunogenicity and safety of a virosomal hepatitis A vaccine in HIV-positive patients.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available


  62. MAYOL K , Munier S, Beck A, Verrier B, et al
    Design and characterization of an HIV-1 Tat mutant: Inactivation of viral and cellular functions but not antigenicity.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available


  63. PANCRE V , Delhem N, Yazdanpanah Y, Delanoye A, et al
    Presence of HIV-1 Nef specific CD4 T cell response is associated with non-progression in HIV-1 infection.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available


  64. BUONAGURO L , Devito C, Tornesello ML, Schroder U, et al
    DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available


  65. LAO-ARAYA M , Puthanakit T, Aurpibul L, Sirisanthana T, et al
    Antibody response to hepatitis B re-vaccination in HIV-infected children with immune recovery on highly active antiretroviral therapy.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available


  66. BUCAY AH
    Clinical hypothesis: Application of AIDS vaccines together with thyroid hormones to increase their immunogenic effect.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available


    April 2007
  67. TASTAN Y
    Comment on Hesseling, et al. "The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children" [Vaccine 25 (2006) 14-18].
    Vaccine. 2007;.
    PubMed     Related articles   


    March 2007
  68. TARANTOLA D , Macklin R, Reed ZH, Kieny MP, et al
    Ethical considerations related to the provision of care and treatment in vaccine trials.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available


  69. CATANZARO AT , Roederer M, Koup RA, Bailer RT, et al
    Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available


  70. KARPENKO LI , Ilyichev AA, Eroshkin AM, Lebedev LR, et al
    Combined virus-like particle-based polyepitope DNA/protein HIV-1 vaccine Design, immunogenicity and toxicity studies.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available


    February 2007
  71. XIN KQ , Sekimoto Y, Takahashi T, Mizuguchi H, et al
    Chimeric adenovirus 5/35 vector containing the clade C HIV gag gene induces a cross-reactive immune response against HIV.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available


Thank you for your interest in scientific medicine.


This AMEDEO Service was made possible thanks to the generous unrestricted educational grants provided by Boehringer Ingelheim and Pfizer.

Amedeo is a Bernd Sebastian Kamps website.

   Design: